Long-term ZYN002 eases irritability in fragile X patients: Trial data
Long-term treatment with ZYN002 cannabidiol gel eased symptoms of irritability in children and adolescents with fragile X syndrome, per trial data.| Fragile X News Today
Long-term treatment with ZYN002 cannabidiol gel eased symptoms of irritability in children and adolescents with fragile X syndrome, per trial data.| Fragile X News Today
Kaerus is planning a proof-of-concept Phase 2 trial for KER-0193 after its fragile X syndrome treatment was found safe in healthy adults.| Fragile X News Today
A single dose of Spinogenix’s investigational oral therapy SPG601 led to significant reductions in a measure of abnormal brain activity among men with fragile X syndrome, according to top-line results from a Phase 2a trial. Announced by Spinogenix in a company press release, the results from the placebo-controlled Phase 2a trial (NCT06413537) were also presented […] The post SPG601 found to reduce measure of abnormal brain activity in fragile X appeared first on Fragile X News Today.| Fragile X News Today – The Web's Daily Resource for Fragile X News
The FDA granted fast track designation to Spinogenix's experimental oral therapy SPG601 to treat fragile X syndrome.| Fragile X News Today
Researchers in Kansas and California will investigate people with the FMR1 premutation who are at risk of developing fragile X-associated tremor/ataxia syndrome (FXTAS), a condition related to fragile X syndrome that develops late in life. The five-year project, supported by a $3.1-million grant from the National Institutes of Health, will study key motor, cognitive, and brain […] The post Researchers to study FXTAS risk in people with FMR1 premutation appeared first on Fragile X News Today.| Fragile X News Today – The Web's Daily Resource for Fragile X News
A Phase 2 clinical trial to test MRM-3379, an experimental oral treatment for fragile X syndrome, is expected to launch in 2025. Mirum Pharmaceuticals announced the plan in a company press release reporting financial results and business updates. It didn’t provide details on the trial’s design or location. In October, Mirum acquired global rights to […] The post Mirum plans 2025 Phase 2 trial testing fragile X treatment appeared first on Fragile X News Today.| Fragile X News Today – The Web's Daily Resource for Fragile X News
Category archive page for News.| Fragile X News Today
Steve Bryson is a science writer for Fragile X News Today with a PhD in biochemistry. He covers the latest news and information on a variety of fragile X topics.| Fragile X News Today
Marisa Wexler is a senior science writer for Fragile X News Today with an MS in cellular and molecular pathology. She covers the latest news and information on a variety of fragile X topics.| Fragile X News Today
Tetra Therapeutics has amended the protocols of two ongoing clinical trials testing zatolmilast to improve access for fragile X patients.| Fragile X News Today
July is Fragile X Awareness Month, and this year, there are many ways to help build and spread knowledge about fragile X syndrome.| Fragile X News Today
